(Equilibrative nucleoside transporter 1 () (ENT) (1) is the major transporter of the chemotherape... more (Equilibrative nucleoside transporter 1 () (ENT) (1) is the major transporter of the chemotherapeutic drug gemcitabine, the current therapy for advanced gallbladder cancer () (GBC) ().) (ENT) (1 expression was proposed as a predictive marker for gemcitabine-treated pancreatic cancer patients. This study explored the value of) (ENT) (1 measurement in chemotherapy-naïve patients with advanced) (GBC) (.) MATERIALS AND RESULTS: (Immunohistochemistry for) (ENT) (1 was performed on 214) (GBC) (samples from patients who had never undergone co- or neo-adjuvant chemotherapy. Advanced) (GBC) (cases were divided into groups with low or high) (ENT) (1 expression. Kaplan-Meier tests were used for survival analyses. The Cox regression method was used to assess the association of) (ENT) (1 expression with overall survival () (OS) (). Low) (ENT) (1 expression was associated with younger patient age (P = 0.03) and moderate-to-poor histological differentiation (P = 0.01).) (pT) (2 patients with low) (ENT) (1 expression had a shorter median survival time (17.3 versus 28.7 months) and lower) (OS) ((17.3% versus 33.3%, P < 0.05) than patients with high) (ENT) (1 expression. Low) (ENT) (1 expression was an independent prognostic factor for) (OS) ((P = 0.036).) CONCLUSIONS: (ENT) (1 is a prognostic marker for) (pT) (2) (GBC) (patients. Additional studies are needed to determine whether) (ENT) (1 has predictive value for gemcitabine response in) (GBC) (.) This article is protected by copyright. All rights reserved.
Thrombotic thrombocytopenic purpura presents as a multisystemic disease with thrombocytopenia, mi... more Thrombotic thrombocytopenic purpura presents as a multisystemic disease with thrombocytopenia, microangiopathic hemolytic anemia, fever, neurological and renal involvement. We report a 24 years-old male presenting with purpura and a generalized ...
Background Approximately half of all patients with advanced EGFR-mutant NSCLC will develop acquir... more Background Approximately half of all patients with advanced EGFR-mutant NSCLC will develop acquired resistance to first or second-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) with a T790M mutation. In the AURA3 trial, patients with a T790M mutation had a response rate of 71% to osimertinib, a third-generation EGFR-TKI. The response to osimertinib may vary according to plasma T790M mutation frequency. Our aim was to determine the effect of plasma T790M mutation load on treatment response to osimertinib in an Australian multi-institutional cohort. Methods We performed a retrospective study on patients treated with osimertinib in the second-line setting and beyond between 2016-2018 from ten centres in Australia, who had T790M mutations detected in tumour or plasma. The primary objective was to investigate if there was a difference in disease control rate (DCR) between patients with high vs. low T790M relative allelic frequency (RAF) as detected in plasma, using a 0.3 RAF cut-...
Massive pulmonary thromboembolism has a high mortality. Early thrombolysis is the treatment of ch... more Massive pulmonary thromboembolism has a high mortality. Early thrombolysis is the treatment of choice. We report a 79-year-old man admitted in shock. A chest angio-CAT scan showed a massive pulmonary thromboembolism. A transthoracic echocardiography showed a right cardiac dysfunction. Although the patient was in hemodynamic instability, he was subjected to thrombolysis with streptokinase, assisted with noradrenaline support and invasive mechanical ventilation. Parenteral anticoagulation was started thereafter. A second echocardiography, performed 72 hours later showed an improvement in right ventricular function. The patient had a nosocomial pneumonia that was treated. Noradrenalin and mechanical ventilation were discontinued nine and 15 days after thrombolysis. A new angio-CAT scan, 23 days after the procedure, was normal. The patient was discharged in good conditions 27 days after admission.
ABSTRACT Massive pulmonary thromboembolism has a high mortality. Early thrombolysis is the treatm... more ABSTRACT Massive pulmonary thromboembolism has a high mortality. Early thrombolysis is the treatment of choice. We report a 79-year-old man admitted in shock. A chest angio-CAT scan showed a massive pulmonary thromboembolism. A transthoracic echocardiography showed a right cardiac dysfunction. Although the patient was in hemodynamic instability, he was subjected to thrombolysis with streptokinase, assisted with noradrenaline support and invasive mechanical ventilation. Parenteral anticoagulation was started thereafter. A second echocardiography, performed 72 hours later showed an improvement in right ventricular function. The patient had a nosocomial pneumonia that was treated. Noradrenalin and mechanical ventilation were discontinued nine and 15 days after thrombolysis. A new angio-CAT scan, 23 days after the procedure, was normal. The patient was discharged in good conditions 27 days after admission.
... 1995;26:3856. 4. Fujimura T, Murakami S, Kuroda T, Nakano M, Shimojo F. A case of ANCA assoc... more ... 1995;26:3856. 4. Fujimura T, Murakami S, Kuroda T, Nakano M, Shimojo F. A case of ANCA associated vasculitis complicated with ... 13. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic ...
(Equilibrative nucleoside transporter 1 () (ENT) (1) is the major transporter of the chemotherape... more (Equilibrative nucleoside transporter 1 () (ENT) (1) is the major transporter of the chemotherapeutic drug gemcitabine, the current therapy for advanced gallbladder cancer () (GBC) ().) (ENT) (1 expression was proposed as a predictive marker for gemcitabine-treated pancreatic cancer patients. This study explored the value of) (ENT) (1 measurement in chemotherapy-naïve patients with advanced) (GBC) (.) MATERIALS AND RESULTS: (Immunohistochemistry for) (ENT) (1 was performed on 214) (GBC) (samples from patients who had never undergone co- or neo-adjuvant chemotherapy. Advanced) (GBC) (cases were divided into groups with low or high) (ENT) (1 expression. Kaplan-Meier tests were used for survival analyses. The Cox regression method was used to assess the association of) (ENT) (1 expression with overall survival () (OS) (). Low) (ENT) (1 expression was associated with younger patient age (P = 0.03) and moderate-to-poor histological differentiation (P = 0.01).) (pT) (2 patients with low) (ENT) (1 expression had a shorter median survival time (17.3 versus 28.7 months) and lower) (OS) ((17.3% versus 33.3%, P < 0.05) than patients with high) (ENT) (1 expression. Low) (ENT) (1 expression was an independent prognostic factor for) (OS) ((P = 0.036).) CONCLUSIONS: (ENT) (1 is a prognostic marker for) (pT) (2) (GBC) (patients. Additional studies are needed to determine whether) (ENT) (1 has predictive value for gemcitabine response in) (GBC) (.) This article is protected by copyright. All rights reserved.
Thrombotic thrombocytopenic purpura presents as a multisystemic disease with thrombocytopenia, mi... more Thrombotic thrombocytopenic purpura presents as a multisystemic disease with thrombocytopenia, microangiopathic hemolytic anemia, fever, neurological and renal involvement. We report a 24 years-old male presenting with purpura and a generalized ...
Background Approximately half of all patients with advanced EGFR-mutant NSCLC will develop acquir... more Background Approximately half of all patients with advanced EGFR-mutant NSCLC will develop acquired resistance to first or second-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) with a T790M mutation. In the AURA3 trial, patients with a T790M mutation had a response rate of 71% to osimertinib, a third-generation EGFR-TKI. The response to osimertinib may vary according to plasma T790M mutation frequency. Our aim was to determine the effect of plasma T790M mutation load on treatment response to osimertinib in an Australian multi-institutional cohort. Methods We performed a retrospective study on patients treated with osimertinib in the second-line setting and beyond between 2016-2018 from ten centres in Australia, who had T790M mutations detected in tumour or plasma. The primary objective was to investigate if there was a difference in disease control rate (DCR) between patients with high vs. low T790M relative allelic frequency (RAF) as detected in plasma, using a 0.3 RAF cut-...
Massive pulmonary thromboembolism has a high mortality. Early thrombolysis is the treatment of ch... more Massive pulmonary thromboembolism has a high mortality. Early thrombolysis is the treatment of choice. We report a 79-year-old man admitted in shock. A chest angio-CAT scan showed a massive pulmonary thromboembolism. A transthoracic echocardiography showed a right cardiac dysfunction. Although the patient was in hemodynamic instability, he was subjected to thrombolysis with streptokinase, assisted with noradrenaline support and invasive mechanical ventilation. Parenteral anticoagulation was started thereafter. A second echocardiography, performed 72 hours later showed an improvement in right ventricular function. The patient had a nosocomial pneumonia that was treated. Noradrenalin and mechanical ventilation were discontinued nine and 15 days after thrombolysis. A new angio-CAT scan, 23 days after the procedure, was normal. The patient was discharged in good conditions 27 days after admission.
ABSTRACT Massive pulmonary thromboembolism has a high mortality. Early thrombolysis is the treatm... more ABSTRACT Massive pulmonary thromboembolism has a high mortality. Early thrombolysis is the treatment of choice. We report a 79-year-old man admitted in shock. A chest angio-CAT scan showed a massive pulmonary thromboembolism. A transthoracic echocardiography showed a right cardiac dysfunction. Although the patient was in hemodynamic instability, he was subjected to thrombolysis with streptokinase, assisted with noradrenaline support and invasive mechanical ventilation. Parenteral anticoagulation was started thereafter. A second echocardiography, performed 72 hours later showed an improvement in right ventricular function. The patient had a nosocomial pneumonia that was treated. Noradrenalin and mechanical ventilation were discontinued nine and 15 days after thrombolysis. A new angio-CAT scan, 23 days after the procedure, was normal. The patient was discharged in good conditions 27 days after admission.
... 1995;26:3856. 4. Fujimura T, Murakami S, Kuroda T, Nakano M, Shimojo F. A case of ANCA assoc... more ... 1995;26:3856. 4. Fujimura T, Murakami S, Kuroda T, Nakano M, Shimojo F. A case of ANCA associated vasculitis complicated with ... 13. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic ...
Uploads
Papers by José Luis Leal Fernández